phenytoin has been researched along with Disease Exacerbation in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phenytoin, one of the most common antiepileptic drugs, is a major cause of antiepileptic drug hypersensitivity syndrome (AHS), which is a rare but potentially fatal complication." | 7.75 | Agranulocytosis following phenytoin-induced hypersensitivity syndrome. ( Imai, K; Ito, S; Oguni, H; Osawa, M; Sasaki, K; Shioda, M, 2009) |
| "Phenytoin, one of the most common antiepileptic drugs, is a major cause of antiepileptic drug hypersensitivity syndrome (AHS), which is a rare but potentially fatal complication." | 3.75 | Agranulocytosis following phenytoin-induced hypersensitivity syndrome. ( Imai, K; Ito, S; Oguni, H; Osawa, M; Sasaki, K; Shioda, M, 2009) |
| "Seventy patients died (unrelated to seizures) and survival rates were equivalent in both groups (median survival = 6." | 2.71 | Prophylactic anticonvulsants in patients with brain tumour. ( Barnes, P; Brasher, PM; Cairncross, JG; DeAngelis, LM; Forsyth, PA; Fulton, D; Hagen, NA; Stewart, D; Sutherland, G; Weaver, S, 2003) |
| "We report a patient with limbic encephalitis associated with RP who presented with anti-glutamate receptor (GluR) epsilon2 (NR2B) autoantibodies in his cerebrospinal fluid and sera." | 1.35 | Autoantibodies to glutamate receptor GluRepsilon2 in a patient with limbic encephalitis associated with relapsing polychondritis. ( Kashihara, K; Kawada, S; Takahashi, Y, 2009) |
| " Further detailed pharmacokinetic studies of irinotecan in patients receiving concomitant therapy with enzyme-inducing anticonvulsants are required so that rational dosing recommendations can be provided for this patient population." | 1.31 | Influence of phenytoin on the disposition of irinotecan: a case report. ( Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarado-Alvarado, JA | 3 |
| Salas-Villela, RA | 3 |
| Reyes-Guerrero, JA | 3 |
| Ezquerra-Osorio, A | 3 |
| Ito, S | 1 |
| Shioda, M | 1 |
| Sasaki, K | 1 |
| Imai, K | 1 |
| Oguni, H | 1 |
| Osawa, M | 1 |
| Miyahara, A | 1 |
| Saito, Y | 1 |
| Sugai, K | 1 |
| Nakagawa, E | 1 |
| Sakuma, H | 1 |
| Komaki, H | 1 |
| Sasaki, M | 1 |
| Kashihara, K | 1 |
| Kawada, S | 1 |
| Takahashi, Y | 1 |
| Forsyth, PA | 1 |
| Weaver, S | 1 |
| Fulton, D | 1 |
| Brasher, PM | 1 |
| Sutherland, G | 1 |
| Stewart, D | 1 |
| Hagen, NA | 1 |
| Barnes, P | 1 |
| Cairncross, JG | 1 |
| DeAngelis, LM | 1 |
| Eriksson, K | 1 |
| Metsäranta, P | 1 |
| Huhtala, H | 1 |
| Auvinen, A | 1 |
| Kuusela, AL | 1 |
| Koivikko, M | 1 |
| Frangogiannis, NG | 1 |
| Boridy, I | 1 |
| Mazhar, M | 1 |
| Mathews, R | 1 |
| Gangopadhyay, S | 1 |
| Cate, T | 1 |
| Merims, D | 1 |
| Kuritzky, A | 1 |
| Bauer, J | 1 |
| Burr, W | 1 |
| Snelson, C | 1 |
| Dieckman, B | 1 |
| Murry, DJ | 1 |
| Cherrick, I | 1 |
| Salama, V | 1 |
| Berg, S | 1 |
| Bernstein, M | 1 |
| Kuttesch, N | 1 |
| Blaney, SM | 1 |
1 review available for phenytoin and Disease Exacerbation
| Article | Year |
|---|---|
Recognizing and managing purple glove syndrome.
Topics: Adult; Anticonvulsants; Disease Progression; Epilepsy, Tonic-Clonic; Extravasation of Diagnostic and | 2000 |
1 trial available for phenytoin and Disease Exacerbation
| Article | Year |
|---|---|
Prophylactic anticonvulsants in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Disease Progression; Female; Humans; Incidence; Male; Middle Aged; | 2003 |
9 other studies available for phenytoin and Disease Exacerbation
| Article | Year |
|---|---|
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.
Topics: Digoxin; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial In | 2022 |
Agranulocytosis following phenytoin-induced hypersensitivity syndrome.
Topics: Agranulocytosis; Anti-Bacterial Agents; Anticonvulsants; Cefepime; Cephalosporins; Chemical and Drug | 2009 |
Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Child; Disease Progression; Electroencephalography | 2009 |
Autoantibodies to glutamate receptor GluRepsilon2 in a patient with limbic encephalitis associated with relapsing polychondritis.
Topics: Amygdala; Anti-Inflammatory Agents; Anticonvulsants; Atrophy; Autoantibodies; Biomarkers; Brain; Car | 2009 |
Treatment delay and the risk of prolonged status epilepticus.
Topics: Administration, Rectal; Anticonvulsants; Benzodiazepines; Child, Preschool; Clinical Protocols; Dise | 2005 |
Cyclophosphamide in the treatment of toxic epidermal necrolysis.
Topics: Adult; Anticonvulsants; Body Surface Area; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclopho | 1996 |
Daily migraine with aura: a new migraine variant.
Topics: Aged; Aged, 80 and over; Disease Progression; Female; Humans; Male; Middle Aged; Migraine with Aura; | 2000 |
Course of chronic focal epilepsy resistant to anticonvulsant treatment.
Topics: Adult; Anticonvulsants; Carbamazepine; Cluster Analysis; Disease Progression; Documentation; Drug Ad | 2001 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2002 |